Table 3.
Odds ratio | 95% CI | p value | |
---|---|---|---|
Multivariate ordered logistic regression analyses | |||
Amygdala (n = 63)a | |||
Age at death | 1.07 | 1.01–1.14 | 0.0179* |
Braak NFT stage | 0.67 | 0.35–1.29 | 0.2320 |
Saito AG stage | 3.18 | 1.73–5.84 | < 0.001** |
LATE-NC stage | 0.62 | 0.27–1.44 | 0.2659 |
Entorhinal cortex (n = 63)a | |||
Age at death | 1.01 | 0.98–1.05 | 0.3961 |
Braak NFT stage | 0.82 | 0.42–1.60 | 0.5656 |
Saito AG stage | 2.38 | 1.29–4.39 | 0.0056** |
LATE-NC stage | 1.94 | 0.89–4.22 | 0.0948 |
CA1 in the hippocampusa | |||
Age at death | 0.76 | 0.55–1.05 | 0.0920 |
Braak NFT stage | 5.37 | 0.50–57.69 | 0.1656 |
Saito AG stage | 220.70 | 1.50–32565.95 | 0.0342* |
LATE-NC stageb | 138.28 | 0.74–25,781.42 | 0.0646 |
Lateral occipitotemporal gyrus (n = 63)a | |||
Age at death | 1.00 | 0.96–1.03 | 0.8281 |
Braak NFT stage | 0.42 | 0.17–1.04 | 0.0619 |
Saito AG stage | 2.82 | 1.39–5.71 | 0.0040** |
LATE-NC stage | 3.93 | 1.43–10.85 | 0.0082** |
Inferior temporal gyrus (n = 63)c | |||
Age at death | 1.01 | 0.92–1.12 | 0.8326 |
Braak NFT stage | 0.41 | 0.14–1.17 | 0.0951 |
Saito AG stage | 2.88 | 1.36–6.11 | 0.0059** |
LATE-NC stage | 2.97 | 1.01–8.77 | 0.0485* |
Middle temporal gyrus (n = 63)a | |||
Age at death | 1.00 | 0.91–1.11 | 0.9727 |
Braak NFT stage | 0.52 | 0.20–1.37 | 0.1854 |
Saito AG stage | 2.92 | 1.34–6.33 | 0.0068** |
LATE-NC stage | 3.74 | 1.24–11.24 | 0.0190* |
Superior temporal gyrus (n = 60)a | |||
Age at death | 1.03 | 0.92–1.16 | 0.6320 |
Braak NFT stage | 0.56 | 0.20–1.56 | 0.2656 |
Saito AG stage | 6.74 | 2.16–21.02 | 0.0010** |
LATE-NC stage | 0.83 | 0.25–2.73 | 0.7634 |
Insular cortex (n = 62)a | |||
Age at death | 0.99 | 0.95–1.04 | 0.8149 |
Braak NFT stage | 0.73 | 0.32–1.68 | 0.4615 |
Saito AG stage | 4.28 | 1.86–9.84 | < 0.001** |
LATE-NC stage | 2.15 | 0.82–5.59 | 0.1179 |
Cingulate gyrus (n = 60)a | |||
Age at death | 1.01 | 0.92–1.12 | 0.7919 |
Braak NFT stage | 0.70 | 0.30–1.63 | 0.4052 |
Saito AG stage | 2.75 | 1.27–5.95 | 0.0100** |
LATE-NC stage | 1.94 | 0.72–5.21 | 0.1891 |
Middle frontal gyrus (n = 63)a | |||
Age at death | 0.96 | 0.87–1.07 | 0.4509 |
Braak NFT stage | 0.52 | 0.20–1.38 | 0.1903 |
Saito AG stage | 5.44 | 2.11–14.01 | < 0.001** |
LATE-NC stage | 1.37 | 0.47–3.96 | 0.5626 |
Orbital gyrus (n = 53)a | |||
Age at death | 0.97 | 0.87–1.07 | 0.5166 |
Braak NFT stage | 0.45 | 0.17–1.23 | 0.1208 |
Saito AG stage | 5.84 | 2.21–15.43 | < 0.001** |
LATE-NC stage | 1.80 | 0.55–5.95 | 0.3326 |
Substantia nigra (n = 63)a | |||
Age at death | 0.94 | 0.84–1.04 | 0.1985 |
Braak NFT stage | 0.73 | 0.28–1.88 | 0.5114 |
Saito AG stage | 2.76 | 1.25–6.09 | 0.0116* |
LATE-NC stage | 1.94 | 0.67–5.60 | 0.2230 |
Binomial logistic regression analysis | |||
Caudate nucleus (n = 63)d | |||
Age at death | 0.87 | 0.75–1.02 | 0.0821 |
Moderate NFTse | 1.71 | 0.07–39.80 | 0.7393 |
Severe AGsf | 20.02 | 1.29–310.27 | 0.0321* |
Moderate LATE-NCg | 53.87 | 1.28–2262.10 | 0.0366* |
Putamen (n = 63)d | |||
Age at death | 0.84 | 0.67–1.05 | 0.1206 |
Moderate NFTse | 0.10 | 0.00–17.44 | 0.3783 |
Severe AGsf | 473.03 | 2.55–87,745.07 | 0.0208* |
Moderate LATE-NCg | 68.84 | 0.22–21,175.06 | 0.1477 |
Globus pallidus (n = 63)d | |||
Age at death | 0.98 | 0.83–1.16 | 0.8167 |
Moderate NFTse | 0.11 | 0.00–6.49 | 0.2895 |
Severe AGsf | 85.90 | 3.24–2277.13 | 0.0077** |
Moderate LATE-NCg | 6.82 | 0.15–317.26 | 0.3270 |
30 pAGD cases and 34 control cases were examined.
CI confidence interval, NFT neurofibrillary tangle, AG argyrophilic grains, LATE-NC limbic-predominant age-related TDP-43 encephalopathy neuropathologic change.
aThe dependent variable was a four-point staging system of neuronal loss (none, mild, moderate, and severe. The definitions are noted in the text) in each region. The age at death, Braak NFT stage, Saito AG stage, and LATE-NC stage were submitted as independent variables.
bLATE-NC stages 1–3 were combined.
cNeuronal loss stages 2 and 3 were combined.
dThe dependent variable was the presence or absence of neuronal loss (stages 0 or 1–3) in each region.
eBraak NFT stages III–IV.
fBecause all diffuse form pAGD cases fit the criteria of Saito AG stage III, diffuse form was regarded as Saito AG stage III in statistical analyses.
gLATE-NC stages 2. No pAGD or control case had LATE-NC in stage 3.
*: p < 0.05, **: p < 0.01